Current AstraZeneca Vice President Respiratory, Inflammation & Autoimmunity James Ward-Lilley will become CEO of Vectura Group as of October 1 2015. Vectura had previously announced that its current CEO, Chris Blackwell, will be stepping down at the end of June 2015. Ward-Lilley, who has held a variety of roles at AstraZeneca over the past 28 years, commented, "I … [Read more...] about James Ward-Lilley to join Vectura as CEO
News
OptiNose announces positive results from Phase 3 trial of intranasal fluticasone for nasal polyps
OptiNose has announced positive results from the 24-week Phase 3 trial of OPN-375, an intranasal fluticasone product for the treatment for nasal polyps based on the company's Bi-Directional Breath-Powered delivery system. The study showed statistically significant reduction in the primary endpoints, nasal congestion/obstruction symptoms as reported by patients and in … [Read more...] about OptiNose announces positive results from Phase 3 trial of intranasal fluticasone for nasal polyps
Copley Scientific publishes updated inhaler testing guide
Copley Scientific has announced the publication of a brochure titled "Quality Solutions for Inhaler Testing, 2015 Edition" which includes a guide for testing of novel and generic OINDPS. The brochure includes an introduction to various types of inhaled drug products and delivery systems, an overview of relevant regulatory and professional organizations around the … [Read more...] about Copley Scientific publishes updated inhaler testing guide
Novoteris gets $2.8 million from Cystic Fibrosis Foundation Therapeutics for inhaled nitric oxide
US-based Novoteris has received a $2.8 million award from Cystic Fibrosis Foundation Therapeutics Inc. (CFFT) for development of Thiolanox inhaled nitric oxide therapy for the treatment of bacterial lung infections in cystic fibrosis patients. The company said that it plans to use the funding for a Phase 2b study which is expected start by the third quarter of 2015. … [Read more...] about Novoteris gets $2.8 million from Cystic Fibrosis Foundation Therapeutics for inhaled nitric oxide
Inhalation Asia to co-publish special inhalation issue of the Asian Journal of Pharmaceutical Sciences
Inhalation Asia will co-publish a special issue of the Asian Journal of Pharmaceutical Sciences (AJPS) that will available to delegates attending the Inhalation Asia 2015 conference, September 9-11 in Shenyang, China, organizers have announced. Editors for the special issue of AJPS are Hui Xin (YY) Ong of the University of Sydney, Oscar Lui of Merck USA, Darragh … [Read more...] about Inhalation Asia to co-publish special inhalation issue of the Asian Journal of Pharmaceutical Sciences
Alexza to stop manufacturing Adasuve for its partners
Alexza Pharmaceuticals has announced that it will suspend production of Adasuve inhaled loxapine for its partners Ferrer and Teva after the third quarter of 2015 "to reduce Alexza's underutilized manufacturing capacity, overhead expenses and related costs, while fulfilling the supply requirements of its commercial partners." The company says that during the … [Read more...] about Alexza to stop manufacturing Adasuve for its partners
Consort Medical revenue up 85%
Consort Medical, parent company of device maker Bespak, has reported an 84.8% increase in revenue from £100 million in FY 2014 to £184.8 million in FY 2015, an increase it attributes largely to 5.8% growth from Bespak and £79 million in revenues from CDMO Aesica, which Consort acquired in November 2014. The company attributes good part of Bespak's revenue growth … [Read more...] about Consort Medical revenue up 85%
FDA approves Zomig nasal spray for pediatric patients
Impax Specialty Pharma has received approval from the FDA to market Zomig zolmitriptan nasal spray for the treatment of migraine in patients 12-17 years of age, the company says. Impax acquired the US rights to Zomig nasal spray from AstraZeneca in 2012. Impax Laboratories President and CEO Fred Wilkinson commented, "Treatment options have been limited for … [Read more...] about FDA approves Zomig nasal spray for pediatric patients
Pulmatrix announces financing, development deal with Mylan, new lead candidate
Pulmatrix has issued a series of announcements regarding financing and its trading status on the NASDAQ exchange, a development deal for its PUR0200 inhaled COPD drug, and a new DPI it is developing, using its iSPERSE dry powder technology, for the treatment of pulmonary fungal infections in cystic fibrosis patients. Earlier this year, the company announced that it … [Read more...] about Pulmatrix announces financing, development deal with Mylan, new lead candidate
Study shows ICS treatment failures increase with age
A study published online June 11 2015 in the American Journal of Respiratory and Critical Care Medicine showed that asthma patients over 30 years of age who were using inhaled corticosteroids experienced a greater proportion of treatment failures than younger patients. Data from 10 clinical trials between 1993 and 2003 gathered by the Asthma Clinical Research … [Read more...] about Study shows ICS treatment failures increase with age